uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Targeting tumor cells based on Phosphodiesterase 3A expression
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cancer Pharmacology and Computational Medicine.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cancer Pharmacology and Computational Medicine.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cancer Pharmacology and Computational Medicine.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical Chemistry.
Show others and affiliations
2017 (English)In: Experimental Cell Research, ISSN 0014-4827, E-ISSN 1090-2422, Vol. 361, no 2, p. 308-315Article in journal (Refereed) Published
Abstract [en]

We and others have previously reported a correlation between high phosphodiesterase 3 A (PDE3A) expression and selective sensitivity to phosphodiesterase (PDE) inhibitors. This indicates that PDE3A could serve both as a drug target and a biomarker of sensitivity to PDE3 inhibition. In this report, we explored publicly available mRNA gene expression data to identify cell lines with different PDE3A expression. Cell lines with high PDE3A expression showed marked in vitro sensitivity to PDE inhibitors zardaverine and quazinone, when compared with those having low PDE3A expression. Immunofluorescence and immunohistochemical stainings were in agreement with PDE3A mRNA expression, providing suitable alternatives for biomarker analysis of clinical tissue specimens. Moreover, we here demonstrate that tumor cells from patients with ovarian carcinoma show great variability in PDE3A protein expression and that level of PDE3A expression is correlated with sensitivity to PDE inhibition. Finally, we demonstrate that PDE3A is highly expressed in subsets of patient tumor cell samples from different solid cancer diagnoses and expressed at exceptional levels in gastrointestinal stromal tumor (GIST) specimens. Importantly, vulnerability to PDE3 inhibitors has recently been associated with co-expression of PDE3A and Schlafen family member 12 (SLFN12). We here demonstrate that high expression of PDE3A in clinical specimens, at least on the mRNA level, seems to be frequently associated with high SLFIV12 expression. In conclusion, PDE3A seems to be both a promising biomarker and drug target for individualized drug treatment of various cancers.

Place, publisher, year, edition, pages
2017. Vol. 361, no 2, p. 308-315
Keywords [en]
Repositioning, Cancer, Therapy, PDE3A, Biomarker
National Category
Cancer and Oncology Cell Biology
Identifiers
URN: urn:nbn:se:uu:diva-339786DOI: 10.1016/j.yexcr.2017.10.032ISI: 000417774300013PubMedID: 29107068OAI: oai:DiVA.org:uu-339786DiVA, id: diva2:1183417
Funder
Swedish Cancer Society, 2016/335Swedish Research Council, 2016-01112Available from: 2018-02-16 Created: 2018-02-16 Last updated: 2018-04-04Bibliographically approved
In thesis
1. Drug Repositioning for Cancer Treatment: Novel Candidate Identification Strategies
Open this publication in new window or tab >>Drug Repositioning for Cancer Treatment: Novel Candidate Identification Strategies
2018 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Regardless of the enormous investments in cancer research and drug development, the proportion of approved drugs in oncology is low compared to other indications, and new avenues are needed. One attractive approach in this regard is drug repositioning where new uses outside the scope of the original medical indications for existing drugs are identified. It offers the advantages of reduced development risks, time and cost over de novo drug discovery pathways.

The main focus of this thesis was to explore and employ different strategies to identify repurposable drug candidates for treatment of cancer. Aiming for this, in the first project we followed a bioinformatics approach to evaluate PDE3A as a drug target and biomarker. We showed that subgroups of tumors, within many different cancer types, overexpress PDE3A (mRNA and protein) and that PDE3A can predict sensitivity to the clinically tested phosphodiesterase inhibitors zardaverine and quazinone (Paper I). In the second project, a novel automated image based microscopy assay was developed and used for detection of apoptotic cells. In a screen the method was successfully used to identify apoptosis inducing compounds. Two of these apoptosis inducers were found to have repurposing potential (Paper II). Moreover, high-throughput combination screening was performed using different cell models. In paper III, monolayer cell cultures were used as cell model to search for combination partners for the anti-parasitic compound mebendazole (a repurposing candidate). As a result, the antipsychotic drug thioridazine was found to have synergistic effect when combined with mebendazol. Finally, a novel drug-combination platform for three-dimensional cell culture based screening, in 384 well formats, was developed. This assay was used to search for combination partners to the anti-parasitic compound nitazoxanide (a repurposing candidate), which was previously reported to specifically target quiescent cancer cells. The screen identified the antifungal agent ketoconazole as selectively toxic to hypoxic and nutrient deprived cancer cells when combined with nitazoxanide (Paper IV). Thus, we have developed/explored several methodological approaches and identified drugs that potentially can be repurposed for treatment of cancer. 

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2018. p. 40
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 1416
Keywords
cancer treatment, drug repositioning, Phosphodiesterase 3A (PDE3A), apoptosis, combination screening
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-338327 (URN)978-91-513-0203-4 (ISBN)
Public defence
2018-02-28, Rosénsalen, Akademiska sjukhuset, ing 95/96 nbv, Uppsala, 09:00 (English)
Opponent
Supervisors
Available from: 2018-02-05 Created: 2018-01-09 Last updated: 2018-04-04

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Nazir, MadihaSenkowski, WojciechNyberg, FridaBlom, KristinEdqvist, Per-Henrik DJarvius, MalinAndersson, ClaesGustafsson, Mats GNygren, PeterLarsson, RolfFryknäs, Mårten

Search in DiVA

By author/editor
Nazir, MadihaSenkowski, WojciechNyberg, FridaBlom, KristinEdqvist, Per-Henrik DJarvius, MalinAndersson, ClaesGustafsson, Mats GNygren, PeterLarsson, RolfFryknäs, Mårten
By organisation
Cancer Pharmacology and Computational MedicineClinical ChemistryExperimental and Clinical Oncology
In the same journal
Experimental Cell Research
Cancer and OncologyCell Biology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 16 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf